Information Provided By: 
Fly News Breaks for March 31, 2015
HPTX, HZNP
Mar 31, 2015 | 07:32 EDT
UBS called the Horizon Pharma (HZNP) deal for Hyperion Therapeutics (HPTX) a nice, strategic fit and one that was accretive. The firm believes the numbers for Horizon's core business remain too low and will have to come up and that management will continue to bring in smart, strategic, accretive assets. UBS reiterated its Buy rating and raised its price target to $30 from $24 on Horizon Pharma shares.
News For HZNP;HPTX From the Last 2 Days
There are no results for your query HZNP;HPTX
